Dr. Van Tine on the Rationale to Evaluate Catequentinib in Synovial Sarcoma

Partner | Cancer Centers | <b>Siteman</b>

Brian A. Van Tine, MD, PhD, discusses the rationale to evaluate catequentinib in synovial sarcoma.

Brian A. Van Tine, MD, PhD, associate professor in the Department of Medicine, director, Sarcoma Program, Division of Medical Oncology, Washington University School of Medicine in St. Louis, medical oncologist, Siteman Cancer Center, discusses the rationale to evaluate catequentinib (Anlotinib) in synovial sarcoma.

Catequentinib is a novel, multi-targeted, oral RTK inhibitor, Van Tine says. In sarcoma, pazopanib (Votrient) is the only oral TKI available to treat patients with most soft-tissue subtypes, Van Tine explains. As such, a goal for the field is to integrate additional TKIs for use in this disease, Van Tine adds.

Catequentinib is being compared with dacarbazine in the ongoing phase 3 APROMISS trial (NCT03016819) in patients with advanced or metastatic synovial sarcoma, leiomyosarcoma, and alveolar soft-part sarcoma, Van Tine says. During the 2021 ASCO Annual Meeting, initial findings from the study were presented from the matured synovial sarcoma cohort. The results demonstrated that catequentinib significantly prolonged progression-free survival compared with dacarbazine in patients with synovial sarcoma who progressed after anthracycline-based therapy. Moreover, this suggests that TKIs other than pazopanib have clinical utility for patients with synovial sarcoma, Van Tine concludes.